CENTOGENE What We Do For Pharma Header Laboratory Scene

What We Do for Pharma

Enabling the Cure of 100 Rare Diseases in 10 Years

Over our 15 years of diagnosing rare disease patients around the world, we have built the world’s largest resource on rare, metabolic, and neurodegenerative diseases. Containing over 600,000 patient samples, and rapidly growing, we leverage multiomic data from our Bio/Databank to reinvent rare disease drug discovery and development.

Redefining What It Means to Be Rare






Diseases Diagnosed

Our Services

CENTOGENE Operationalising Clinical Trials Laboratory Scene

Clinical Trial Support

We support pharmaceutical companies with a broad range of services to operationalize clinical trials.

Learn more

CENTOGENE Patient Identification Physician Talks to People

Patient Identification

We can identify and stratify patients to help partners target drugs to the most appropriate patients.

Learn more

CENTOGENE Drug Discovery Development Man Looks Into Screen

Drug Discovery R&D Collaborations

We develop new disease models, identify drug targets, and screen compounds to identify potential new drug candidates.

Learn more


At CENTOGENE, we are committed to enabling the cure of 100 rare diseases within 10 years – working alongside over 30 partners via patient identification, clinical trial support, and drug discovery R&D collaborations.

CENTOGENE Pharma Partner Logo Denali

Understanding the Molecular Characteristics of Parkinson’s Disease

ROPAD Study to genotype up to 12,500 patients with Parkinson’s disease globally

Learn more

Identifying Patients With Frontal Temporal Dementia

EFRONT study to better understand the genetics of dementia and raise disease awareness

Learn more

CENTOGENE Pharma Partner Logo Takeda

Diagnosing Patients With Genetic Disorders

Providing access to genetic testing to patients around the world

Learn more

CENTOGENE Pharma Partner Logo Evotec

Turning Insights Into Precision Medicine

Combining hit discovery with CENTOGENE´s novel disease insights to derive investigational new drug (IND) enabling therapies for Gaucher disease

Learn more

Get in Touch With Our Business Development Team

Call us

+49 (0) 381 80 113 - 416

Mon. – Fri. 7 a.m. – 6:30 p.m. CET

Sat. 8 a.m. – 12 p.m. CET

Email us

Send us a message

We aim to reply within 48 hours